SCHEMBL18395376

SCHEMBL18395376

Cn1cc(C[C@@H](NC(=O)[C@@H](N)CCCCN)C(=O)O)c2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MMP9 P14780 1/20 0.46
▸ MMP8 P22894 1/20 0.46
▸ ADAM17 P78536 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ HTR2A P28223 1/20 0.43
▸ MMP2 P08253 1/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ ERAP2 Q6P179 1/20 0.41
▸ ERAP1 Q9NZ08 1/20 0.41
▸ LNPEP Q9UIQ6 1/20 0.41
▸ ARG1 P05089 1/20 0.40
▸ CNR2 P34972 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30023820 1.00 MMP9 (0.46) MMP9MMP8ADAM17KDM4EHPGD
Hydrochloric Acid SCHEMBL18395638 0.99 MMP9 (0.46) MMP9MMP8ADAM17KDM4EHPGD
SCHEMBL30023951 0.96 ADAM17 (0.46) MMP9MMP8ADAM17KDM4EHPGD
Sulfuric Acid SCHEMBL18395441 0.96 ADAM17 (0.46) MMP9MMP8ADAM17KDM4EHPGD
Sulfuric Acid SCHEMBL21747174 0.96 ADAM17 (0.46) MMP9MMP8ADAM17KDM4EHPGD
SCHEMBL18396400 0.96 ADAM17 (0.46) MMP9MMP8ADAM17KDM4EHPGD
Phosphoric Acid SCHEMBL18396350 0.96 MMP9 (0.44) MMP9MMP8ADAM17KDM4EHPGD
Sulfuric Acid SCHEMBL18395438 0.96 ADAM17 (0.46) MMP9MMP8ADAM17KDM4EHPGD
Phosphoric Acid SCHEMBL30024502 0.96 MMP9 (0.44) MMP9MMP8ADAM17KDM4EHPGD
Sulfuric Acid SCHEMBL30024742 0.96 ADAM17 (0.46) MMP9MMP8ADAM17KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3613420-B1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA INC (US) 2022-05-25 — — EP claimed
CN-111004167-A Salts and prodrugs of 1-methyl-D-tryptophan 新联基因公司 2020-04-14 — — CN claimed
EP-3613420-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN Newlink Genetics Corporation (US) 2020-02-26 — — EP claimed
US-10207990-B2 Salts and prodrugs of 1-methyl-D-tryptophan NEWLINK GENETICS CORPORATION (US) 2019-02-19 — — US claimed
US-20180134658-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA, INC. 2018-05-17 — — US claimed
US-9732035-B2 Salts and prodrugs of 1-methyl-D-tryptophan NEWLINK GENETICS CORPORATION (US) 2017-08-15 — — US claimed
US-20170022157-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA, INC. 2017-01-26 — — US claimed
CN-111004167-B Salts and prodrugs of 1-methyl-D-tryptophan 新联基因公司 2024-03-22 — — CN disclosed
EP-3613420-B1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA INC (US) 2022-05-25 — — EP disclosed
EP-3613420-B1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA INC (US) 2022-05-25 — — EP disclosed
EP-3954369-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN Lumos Pharma, Inc. (US) 2022-02-16 — — EP disclosed
EP-3324958-B1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA INC (US) 2021-07-28 — — EP disclosed
EP-3324958-B1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA INC (US) 2021-07-28 — — EP disclosed
US-20180134658-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA, INC. 2018-05-17 — — US disclosed
US-9732035-B2 Salts and prodrugs of 1-methyl-D-tryptophan NEWLINK GENETICS CORPORATION (US) 2017-08-15 — — US disclosed
US-9732035-B2 Salts and prodrugs of 1-methyl-D-tryptophan NEWLINK GENETICS CORPORATION (US) 2017-08-15 — — US disclosed
US-9732035-B2 Salts and prodrugs of 1-methyl-D-tryptophan NEWLINK GENETICS CORPORATION (US) 2017-08-15 — — US disclosed
US-20170022157-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA, INC. 2017-01-26 — — US disclosed
US-20170022157-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA, INC. 2017-01-26 — — US disclosed
US-20170022157-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN LUMOS PHARMA, INC. 2017-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10207990-B2 Salts and prodrugs of 1-methyl-D-tryptophan IDO1, IDO2, INMT MMP9 375/4885MMP8 629/4885ADAM17 2252/4885
US-20170022157-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN IDO1, IDO2, INMT MMP9 375/4885MMP8 629/4885ADAM17 2252/4885
US-20180134658-A1 SALTS AND PRODRUGS OF 1-METHYL-D-TRYPTOPHAN IDO1, IDO2, INMT MMP9 375/4885MMP8 629/4885ADAM17 2252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback